Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.

Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.

The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine such as hydralazine hydrochloride that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina ischaemic heart disease arterial hypertension and related disease conditions. Preferably the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable diffusion and/or osmotic-controlled release profi...

Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that upon administration to a patient delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subsequ...

The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that upon administration to a patient delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subseque...

The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine such as hydralazine hydrochloride that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina ischaemic heart disease arterial hypertension and related disease conditions. Preferably the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable diffusion and/or osmotic-controlled release profi...

The present invention provides a composition comprising a cefditoren or a salt derivative prodrug or other form thereof for example cefditoren pivoxil useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren or a salt derivative prodrug or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less t...

The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate improved bioavailability and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.